Immune Cell Response during COVID-19 Infection and following SARS-CoV-2 Vaccination in Patients Admitted to Intensive Care Unit

Table 1

Patients characteristics.

	Overall patients	Unvaccinated patients	Vaccinated patients	p-value
Total, n (%)	94 (100%)	50 (53.19%)	44 (46.8%)	0.22
Mean age	67.84	65.82	70.14	0.079
Min–max	22–94	24–91	22–94
Sex ratio (F/M)	0.67	0.51	0.91	0.2
Female	38	17	21
Male	56	33	23
Comorbidities
Hypertension	57 (60.6%)	29 (30.85%)	28 (29.78%)	0.57
Diabetes	34 (36.17%)	19 (20.21%)	15 (15.95%)	0.83
Chronic kidney disease	8 (8.51%)	6 (6.38%)	2 (2.12%)	0.27
Dyslipidemia	7 (7.44%)	3 (3.19%)	4 (4.25%)	0.7
Chronic lung disease	3 (3.19%)	0	3 (3.19%)	0.098
Cardiovascular disease	8 (8.51%)	2 (2.12%)	6 (6.38%)	0.14
Stented coronary artery	10 (10.63%)	4 (4.25%)	6 (6.38)	0.5
Asthma	4 (4.25%)	2 (2.12%)	2 (2.12%)	–
Stroke	4 (4.25%)	3 (3.19%)	1 (3.19%)	0.62
Neurological disorders	5 (5.31)	2 (2.12%)	3 (3.19%)	0.66
Obesity	3 (3.19%)	1 (1.06%)	2 (2.12%)	0.59
Smoking patients
Yes	14 (14.89%)	6 (6.38%)	8 (8.50%)	0.56
No	80 (85.1%)	44 (88%)	36 (81.81%)
History of COVID-19 infection	2 (2.12%)	0	2 (2.12%)	0.21
Deceased	59 (62.76%)	33 (35.1%)	26 (27.65%)	0.52
Discharged	35 (37.23%)	17 (18.08%)	18 (19.14%)	0.52
Treatment
Vitaminotherapy	94 (100%)	50 (53.19%)	44 (46.8%)	–
Glucocorticoids	92 (98%)	49 (98%)	43 (98%)	0.92
Antibiotic treatment	92 (96.8%)	49 (98%)	43 (98%)	0.92
Oxygen support	94 (100%)	50 (53.19%)	44 (53.19%)	–